IO Biotech, Inc. IOBTQ
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $3.5M
- P/E
- 0.0×
Follow IOBTQ
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.87 | 1.85 | 21.52 | 13.88 | 9.37 | 3.33 |
Net Debt/EBITDA |
— | (0.08) | 0.34 | 5.13 | 2.00 | 1.57 | 0.63 |
Debt/Assets |
0.00% | 91.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (5.89) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.71 | 0.68 | 0.54 | 0.84 | 0.83 | 0.86 |
Capex/Depreciation |
— | — | — | (76.50) | (6.63) | (1.50) | (0.17) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 42.55% | 49.61% | (84.91%) | (40.74%) | (63.29%) | (106.00%) | |
| — | (265.67%) | (193.61%) | (65.80%) | (38.20%) | (56.91%) | (87.44%) | |
ROIC |
— | 0.00% | 0.00% | (6,557.57%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 869.84% | (564.56%) | (35.44%) | (51.67%) | (65.02%) | (207.13%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.31) | (56.19) | (9.41) | (2.10) | (1.65) | (1.25) |
Cash per Share |
— | 0.27 | 19.22 | 48.78 | 4.95 | 3.29 | 0.91 |
Shareholders Equity per Share |
— | (0.05) | (199.23) | 48.88 | 4.82 | 3.06 | 0.71 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.05) | (199.23) | 48.88 | 4.82 | 3.06 | 0.71 |
Free Cash Flow |
— | (8.89) | (9.96) | (40.80) | (60.42) | (72.06) | (82.39) |
Working Capital |
— | (1.44) | 2.59 | 211.43 | 137.54 | 131.54 | 45.47 |
Capital Expenditures |
— | — | — | (0.15) | (0.69) | (0.32) | (0.04) |
Net Current Asset Value |
— | (1.49) | (35.32) | 211.37 | 135.27 | 129.70 | 44.27 |
| Other line items | |||||||
Quick Ratio |
— | 0.84 | 1.12 | 20.53 | 13.36 | 9.11 | 3.08 |
Depreciation/Fixed assets |
— | — | — | 0.01 | 0.14 | 0.25 | 0.40 |
Cash ROIC |
— | (59.12%) | 31.21% | (9.64%) | (21.49%) | (26.26%) | (77.52%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.31) | (56.19) | (9.37) | (2.07) | (1.65) | (1.25) |
Capex per Share |
— | 0.00 | 0.00 | (0.04) | (0.02) | (0.01) | 0.00 |
Average Receivables |
— | 1.37 | 1.37 | 1.80 | 1.81 | — | — |
Average Payables |
— | 0.76 | 0.76 | 2.23 | 3.97 | 3.94 | 4.27 |
Average Assets |
— | 4.71 | 7.54 | 113.97 | 187.05 | 151.26 | 109.21 |
Average Common Equity |
— | (29.42) | (29.42) | 88.31 | 175.39 | 136.01 | 90.09 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates